Although moxidectin has a wide margin of safety when used at labeled doses, exposure to large animal doses can lead to life-threatening toxicosis in dogs. Common clinical signs include tremors, ataxia, hypersalivation, mydriasis, depression, seizures, and, in severe cases, respiratory complications, coma or death. Early recognition and intervention are critical to managing the effects of toxin exposure and minimizing the risk of severe complications.
In this webinar, Akaterina Davros, DVM, DACVECC, shares clinical insights from a recent moxidectin toxicity case. Dr. Davros reviews key pharmacokinetic properties of this commonly used dewormer and walks through her assessment and treatment approach, including the clinical considerations behind incorporating hemoperfusion (an extracorporeal treatment method designed to remove circulating toxins) into this patient’s care.
Key Talking Points Include:
- Understanding moxidectin toxicity in dogs
- Reviewing treatment considerations for a severe moxidectin overdose
- Exploring the role of hemoperfusion in toxin removal
